Should I buy or sell Cassava Sciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SAVA shares. View SAVA analyst ratings or view top-rated stocks .

What is Cassava Sciences' stock price target for 2024?

1 Wall Street analysts have issued 1-year price targets for Cassava Sciences' shares. Their SAVA share price targets range from $124.00 to $124.00. On average, they anticipate the company's stock price to reach $124.00 in the next twelve months. This suggests a possible upside of 529.4% from the stock's current price. View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts .

How have SAVA shares performed in 2024?

Cassava Sciences' stock was trading at $22.51 at the beginning of the year. Since then, SAVA stock has decreased by 12.5% and is now trading at $19.70. View the best growth stocks for 2024 here .

When is Cassava Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our SAVA earnings forecast .

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) posted its earnings results on Wednesday, February, 28th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.10.

What ETFs hold Cassava Sciences' stock?

ETFs with the largest weight of Cassava Sciences (NASDAQ:SAVA) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and iShares Neuroscience and Healthcare ETF (IBRN) . iShares U.S. Pharmaceuticals ETF (IHE) .

When did Cassava Sciences' stock split?

Cassava Sciences shares split on Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly minted shares were payable to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split.

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO) , NVIDIA (NVDA) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) , Advanced Micro Devices (AMD) , NIO (NIO) , DURECT (DRRX) , Tesla (TSLA) , OPKO Health (OPK) and Alibaba Group (BABA) .

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.06%) and NBC Securities Inc. (0.02%). Insiders that own company stock include Eric Schoen, James William Kupiec, Richard Barry and Sanford Robertson. View institutional ownership trends .

How do I buy shares of Cassava Sciences?

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SAVA

Cassava Sciences (SAVA) Stock Price, News & Analysis

→ Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report (From Darwin) (Ad)

Free SAVA Stock Alerts

$19.70

-1.49 (-7.03%)

(As of 01:58 PM ET)

Compare

Today's Range: $19.60
▼
$21.20
50-Day Range: $18.44
▼
$26.11
52-Week Range: $12.32
▼
$32.10

Volume: 833,636 shs
Average Volume: 764,991 shs
Market Capitalization: $852.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $124.00

Get Cassava Sciences alerts:

Cassava Sciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 529.4% Upside
$124.00 Price Target
Short Interest: Bearish
27.26% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.82
Upright™ Environmental Score
News Sentiment: 0.32
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.01) to $1.67 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.49 out of 5 stars

Medical Sector

268th out of 918 stocks

Pharmaceutical Preparations Industry

110th out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
Cassava Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cassava Sciences has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
27.26% of the outstanding shares of Cassava Sciences have been sold short.
Short Interest Ratio / Days to Cover
Cassava Sciences has a short interest ratio ("days to cover") of 17, which indicates bearish sentiment.
Change versus previous month
Short interest in Cassava Sciences has recently decreased by 1.42%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Cassava Sciences does not currently pay a dividend.
Dividend Growth
Cassava Sciences does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Cassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Cassava Sciences is -0.82.

3.0

News and Social Media Coverage

News Sentiment
Cassava Sciences has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Cassava Sciences this week, compared to 5 articles on an average week.
Search Interest
35 people have searched for SAVA on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
MarketBeat Follows
36 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 140% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cassava Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.00% of the stock of Cassava Sciences is held by insiders.
Percentage Held by Institutions
Only 38.05% of the stock of Cassava Sciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cassava Sciences are expected to grow in the coming year, from ($2.01) to $1.67 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cassava Sciences is -8.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cassava Sciences is -8.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cassava Sciences has a P/B Ratio of 6.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

About Cassava Sciences Stock (NASDAQ:SAVA)

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

SAVA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SAVA Stock News Headlines

April 19, 2024 | finance.yahoo.com

Cassava Sciences, Inc. (SAVA)

April 15, 2024 | globenewswire.com

Redemption Date Announced for Warrants

April 19, 2024 | DTI (Ad)

Special FREE offer on stock hotsheets

These sheets tell you the exact day you should consider buying a stock… And the exact day you should consider selling it… All based on TEN YEARS of historic data and trends. For example, like January 6th through the 12th with Apple… It’s gone up every single year for the last decade. Or like May 26th through June 11th with LULU… Again - it’s gone up every single year for the last decade. Then there’s July 1st through the 21st with Walmart… What happened to WMT?

April 15, 2024 | americanbankingnews.com

Contrasting Cassava Sciences (NASDAQ:SAVA) & Nabriva Therapeutics (NASDAQ:NBRV)

April 14, 2024 | americanbankingnews.com

Cassava Sciences (NASDAQ:SAVA) Shares Down 9%

April 12, 2024 | americanbankingnews.com

Cassava Sciences Sees Unusually Large Options Volume (NASDAQ:SAVA)

April 5, 2024 | bizjournals.com

Ag nonprofit launched by Gates Foundation opens HQ in Cortex, grows to 30 employees

April 4, 2024 | msn.com

Strong quake rocks Taiwan, tsunami warnings issued

April 19, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

April 3, 2024 | ft.com

Can Africa one day help feed the world’s growing population?

April 2, 2024 | stockhouse.com

24 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

April 2, 2024 | msn.com

Tracing science’s transformative impact on manifesto implementation

April 1, 2024 | stockhouse.com

FINAL SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit!

March 29, 2024 | prnewswire.com

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

March 29, 2024 | finance.yahoo.com

SAVA Apr 2024 17.000 put

March 28, 2024 | msn.com

Cassava: How Nutrition Professionals Assess Its Health Benefits, Nutrition Facts, And More

March 28, 2024 | markets.businessinsider.com

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava Sciences

March 27, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA

March 26, 2024 | au.investing.com

Cassava Sciences' Alzheimer's drug continues Phase 3 trials

March 25, 2024 | seekingalpha.com

Cassava Sciences: New Year, Same Game Of Smoke And Mirrors

March 25, 2024 | markets.businessinsider.com

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

March 25, 2024 | globenewswire.com

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

March 24, 2024 | stockhouse.com

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

March 23, 2024 | stockhouse.com

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

March 23, 2024 | markets.businessinsider.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

March 21, 2024 | prnewswire.com

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

March 20, 2024 | stockhouse.com

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm

See More Headlines

Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/06/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SAVA
CUSIP: N/A
CIK: 1069530
Web: www.cassavasciences.com
Phone: (512) 501-2444
Fax: 512-501-0414
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $124.00
High Stock Price Target: $124.00
Low Stock Price Target: $124.00
Potential Upside/Downside: +504.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-97,220,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -57.53%
Return on Assets: -52.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.13
Quick Ratio: 9.13

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.26 per share
Price / Book: 6.29

Miscellaneous

Outstanding Shares: 43,250,000
Free Float: 39,354,000
Market Cap: $887.49 million
Optionable: Optionable
Beta: -0.45

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Remi Barbier (Age 64)
Founder, Chairman, President & CEO
Comp: $1.2M
Mr. Eric J. Schoen (Age 56)
Chief Financial Officer
Comp: $460k
Mr. R. Christopher Cook (Age 60)
Senior VP, Company Secretary & General Counsel
Comp: $425k
Dr. James W. Kupiec M.D. (Age 71)
Chief Medical Officer
Comp: $435k
Dr. George Thornton Ph.D.
Senior Vice President of Technology
Mr. Michael Zamloot
Senior Vice President of Technical Operations
Dr. Michael Marsman Pharm.D.
Senior Vice President of Regulatory Affairs
Dr. Lindsay H. Burns Ph.D.
Senior Vice President of Neuroscience

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SAVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Cassava Sciences stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SAVA shares.
View SAVA analyst ratings or view top-rated stocks.
What is Cassava Sciences' stock price target for 2024?: 1 Wall Street analysts have issued 1-year price targets for Cassava Sciences' shares. Their SAVA share price targets range from $124.00 to $124.00. On average, they anticipate the company's stock price to reach $124.00 in the next twelve months. This suggests a possible upside of 529.4% from the stock's current price.
View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts.
How have SAVA shares performed in 2024?: Cassava Sciences' stock was trading at $22.51 at the beginning of the year. Since then, SAVA stock has decreased by 12.5% and is now trading at $19.70.
View the best growth stocks for 2024 here.
When is Cassava Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our SAVA earnings forecast.
How were Cassava Sciences' earnings last quarter?: Cassava Sciences, Inc. (NASDAQ:SAVA) posted its earnings results on Wednesday, February, 28th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.10.
What ETFs hold Cassava Sciences' stock?: ETFs with the largest weight of Cassava Sciences (NASDAQ:SAVA) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and iShares Neuroscience and Healthcare ETF (IBRN).iShares U.S. Pharmaceuticals ETF (IHE).

When did Cassava Sciences' stock split?: Cassava Sciences shares split on Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly minted shares were payable to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split.
What other stocks do shareholders of Cassava Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).
Who are Cassava Sciences' major shareholders?: Cassava Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.06%) and NBC Securities Inc. (0.02%). Insiders that own company stock include Eric Schoen, James William Kupiec, Richard Barry and Sanford Robertson.
View institutional ownership trends.
How do I buy shares of Cassava Sciences?: Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SAVA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial